Merck Acquires Terns Pharmaceuticals for $6.7B

On March 25, 2026, Merck made headlines with one of the biggest biotech deals of the year: a $6.7 billion all-cash acquisition of Terns Pharmaceuticals. The deal, priced at $53 per share, sent Terns stock surging more than 5% and signals how aggressively the pharmaceutical giant is racing to secure its future before a looming revenue crisis hits in 2028. For investors, analysts, and healthcare watchers, this acquisition is a defining moment — both for what it reveals about Merck's strategy and what it says about the future of cancer treatment.

Why Merck Is Buying Terns Pharmaceuticals

The short answer: Keytruda. Merck's blockbuster immunotherapy drug accounts for nearly half of the company's total sales — more than $30 billion annually — and it faces generic competition starting in 2028. That patent cliff has set off alarm bells inside Merck's boardroom, triggering a multi-year acquisition spree designed to fill the gap before it becomes a crater.

The Terns deal is Merck's third multibillion-dollar acquisition in the past year alone, following its $9.2 billion purchase of Cidara Therapeutics and its $10 billion acquisition of Verona Pharma. Together, these moves represent a calculated bet that Merck can build a diversified oncology and hematology pipeline robust enough to absorb the Keytruda shock.

The crown jewel of the Terns acquisition is TERN-701, an oral allosteric BCR::ABL tyrosine kinase inhibitor targeting chronic myeloid leukemia (CML). Merck CEO Robert Davis was unambiguous about its importance, calling TERN-701 a "significant driver of growth in the next decade." For a company staring down a $30 billion revenue gap, that kind of confidence isn't marketing — it's a strategic lifeline. You can read more about the deal's strategic rationale via CNBC's full coverage.

What Is TERN-701 and Why Does It Matter?

TERN-701 is an oral, allosteric inhibitor of the BCR::ABL fusion protein — the molecular driver behind chronic myeloid leukemia, a blood cancer affecting tens of thousands of patients in the United States each year. Unlike existing CML therapies, TERN-701 targets the allosteric binding site of the BCR::ABL protein, which may allow it to overcome resistance mechanisms that cause patients to fail on current treatments.

The clinical data behind TERN-701 is what has analysts and oncologists paying close attention:

• Phase 1 trial results presented at the American Society of Hematology (ASH) meeting in December 2025 showed a major molecular response (MMR) rate of up to 75% at 24 weeks — a result described by observers as unprecedented for this stage of development.
• The drug demonstrated a tolerable safety profile, a critical factor in CML treatment where long-term tolerability often determines patient adherence.
• TERN-701 received FDA Orphan Drug Designation in March 2024, granting it regulatory incentives including a seven-year market exclusivity period post-approval.

The market opportunity is substantial. Up to 40% of CML patients treated with existing tyrosine kinase inhibitors switch therapies within five years, driven by side effects, resistance, or inadequate response. That represents a large, addressable population for a drug that could offer better tolerability and efficacy in patients who have failed prior lines of therapy. FierceBiotech has a detailed breakdown of why TERN-701's profile stands out in the CML landscape.

Deal Structure and What Investors Should Know

The acquisition is structured as an all-cash deal at $53 per share, representing:

• A 6% premium over Terns' closing price of $50 on the day before the announcement
• A 31% premium over Terns' 60-day average stock price, reflecting the longer-term value Merck assigns to the pipeline
• A total equity value of approximately $6.7 billion

The deal is expected to close in Q2 2026, subject to regulatory approval and customary closing conditions. Terns shares rose more than 5% on the day of the announcement, while Merck shares climbed approximately 1–2%, suggesting the market views the deal favorably for both parties.

However, not everyone agrees the price is right. Analysts at William Blair argued the deal undervalues TERN-701, citing the drug's differentiated mechanism and the depth of unmet need in the CML market. Meanwhile, Mizuho analysts suggested the deal valuation may leave room for a competing bid — a signal that other large pharma companies may have been watching Terns closely. Whether a counter-offer materializes before deal close remains a key variable for investors to monitor. Yahoo Finance covers the analyst reactions in depth.

Merck's Broader Pipeline Strategy Ahead of the Keytruda Cliff

To fully appreciate why Merck is spending at this velocity, consider the mathematics of the Keytruda patent expiration. A drug generating more than $30 billion per year doesn't just face competition when patents expire — it faces potential revenue collapse as biosimilars enter the market at dramatically lower price points. Merck needs to build replacement revenue streams fast, and organic drug development timelines don't move fast enough.

The acquisition strategy is therefore deliberate and diversified:

• Verona Pharma ($10B) — focused on respiratory diseases, adding non-oncology revenue diversification
• Cidara Therapeutics ($9.2B) — antifungal pipeline, addressing infectious disease markets
• Terns Pharmaceuticals ($6.7B) — hematologic oncology, targeting CML with a potentially best-in-class asset

Together, these three deals represent roughly $26 billion in committed capital over 12 months — an extraordinary pace of dealmaking that underscores the urgency inside Merck. The company is effectively paying a premium today to avoid a catastrophic revenue gap tomorrow. MSN's health coverage offers additional context on how TERN-701 fits into Merck's blood cancer ambitions specifically.

What This Means for the Biotech M&A Landscape in 2026

The Terns acquisition doesn't exist in a vacuum. It's part of a broader wave of large-cap pharma companies aggressively hunting for late-stage clinical assets as their own pipelines mature and key patents expire. The pattern is consistent across the industry: companies with patent cliffs on the horizon deploy capital at scale into companies with mid-to-late stage differentiated drugs.

For smaller biotech companies with compelling clinical data — particularly in oncology and rare diseases — this environment represents a favorable exit landscape. Orphan drug designations, strong Phase 1 data, and unmet medical need in well-defined patient populations are the attributes attracting premium acquisition multiples.

The fact that analysts are already speculating about competing bids for Terns suggests that Merck may have moved decisively to prevent an auction process. Whether that speed came at the cost of a lower price — as William Blair implies — is a question that will be debated as the deal progresses toward close. Full details of the official announcement can be found at Business Insider Markets.

Frequently Asked Questions About the Merck–Terns Pharmaceuticals Acquisition

What is Terns Pharmaceuticals known for?

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company best known for developing TERN-701, an oral allosteric BCR::ABL tyrosine kinase inhibitor designed to treat chronic myeloid leukemia (CML). The drug achieved a 75% major molecular response rate at 24 weeks in Phase 1 trials and received FDA Orphan Drug Designation in March 2024.

How much is Merck paying for Terns Pharmaceuticals?

Merck is acquiring Terns Pharmaceuticals for $53 per share in cash, valuing the company at approximately $6.7 billion in total equity value. This represents a 31% premium over Terns' 60-day average stock price prior to the announcement.

Why is Merck acquiring Terns Pharmaceuticals?

Merck is building its oncology pipeline ahead of the 2028 patent expiration of Keytruda, its top-selling cancer immunotherapy that generates more than $30 billion in annual revenue. TERN-701's strong clinical data and differentiated mechanism in CML make Terns a strategic fit for Merck's hematology ambitions.

When will the Merck–Terns deal close?

The deal is expected to close in the second quarter of 2026, pending regulatory approval and standard closing conditions. Both companies have approved the transaction at the board level.

Could another company make a competing bid for Terns Pharmaceuticals?

Analysts at Mizuho have noted that the deal's valuation may leave room for a competing bid, given TERN-701's clinical promise. However, all-cash deals structured at announced premiums typically move quickly to close, and any competing offer would need to materialize before the deal receives regulatory clearance.

Conclusion: A High-Stakes Bet on the Future of Cancer Treatment

Merck's $6.7 billion acquisition of Terns Pharmaceuticals is more than a headline deal — it is a window into how the pharmaceutical industry is evolving under the pressure of patent expirations, competitive pipelines, and the urgent need for the next generation of breakthrough therapies. TERN-701's impressive Phase 1 data, orphan drug status, and large addressable patient population make it a genuinely compelling asset, and Merck's willingness to pay a 31% premium over Terns' trading average reflects that conviction.

For investors, the deal raises immediate questions: Is $6.7 billion the right price? Could a competing bidder emerge? And can TERN-701 live up to its Phase 1 promise in larger trials? For patients living with CML — particularly those who have struggled with the side effects or resistance to existing tyrosine kinase inhibitors — the answer to that last question matters most of all. With the full weight of Merck's resources behind it, TERN-701's path to approval just got significantly shorter.